Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2016–2021

MarPipe · Improving the flow in the pipeline of the next generation of marine biodiscovery scientists

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-11-01 → 2021-04-30
Финансиране от ЕС
2 853 005 €
Участници
14
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Морските организми и микроби от дълбоководни окопани се анализират за откриване на биологично активни молекули, които действат срещу рак и инфекции. Тези вещества могат да помогнат за лечението на болести, свързани със стареенето на населението.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Improving the flow in the pipeline of the next generation of marine biodiscovery scientists

Marine organisms possess the capacity to produce a variety of unique and biologically potent natural products. Novel molecules might display their activity through new mechanisms of action and therefore could be used to treat human diseases and enhance the quality of life, especially as regards ageing of the population. According to the WHO by 2040 the global population aged 65 and over is estimated to reach 1.3 billion and consequently the prevalence of age-related diseases (e.g. cardiovascular diseases, metabolic disorders, neurodegenerative diseases, cancer and infectious diseases) will increase dramatically. Despite unprecedented interest in marine natural products (MNP) as potential therapeutic agents for a variety of human age-related diseases, relatively few MNP have reached the late stages of the clinical development and the market. To fully exploit the marine biological resources, new strategies in the marine biodiscovery pipeline are needed to overcome existing bottlenecks and ensure the production of high value biomolecules. The specific scientific objectives of MarPipe were therefore to: 1. Further develop hits already identified in 10 strains by MarPipe partners in ongoing EU projects (e.g. PharmaSea, MaCuMBA), in the anti-infective and anticancer fields (hereafter called “Magnificent 10”). 2. Analyse microorganisms that are currently uncultivable and improve methods of their cultivation and co-cultivation in order to optimize production of bioactives compounds. Samples will be provided by the Eurofleet2- Pharmadeep cruise in December 2015 in sub Antarctic deep-sea trenches (Drake Passage, 5000 m). 3. Apply functional bioassays by using metabolic engineering for the discovery of molecular pathways, or apply OSMAC and co-cultivation techniques to awaken silent biosynthetic pathways. 4. Apply sophisticated analytical methods and develop new protocols for the stimulation (of biosynthesis), extraction, isolation, purification and enrichment of biomolecules. 5. Apply medicinal chemistry approaches to optimize the efficacy of target molecules. 6. Scale-up production processes through flexible bioreactor technologies. 7. Address legal and policy constraints in the drug discovery pipeline. 8. Develop innovation and business strategies for drug biodiscovery.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

MarPipe is a consortium of 11 partners (IBP-CNR, SZN, UiT, UNIABDN, GEOMAR, KULeuven, UCC, eCOAST, MEDINA, MicroDish, Italbiotec) based in 8 countries (I, N, UK, D, B, IRL, E, NL), including 3 from the non-academic sector. We will train 11 ESRs in marine drug-discovery, providing these researchers with unique skills toward becoming world leaders in this research field and to advance their careers in academia or industry. MarPipe PhDs will be trained in a programme including training-by-research, joint courses of technical, scientific and transferrable skills, active participation to public scientific events, and an intense inter-sectoral networking exchange plan. Marine organisms have the capacity to produce a variety of biologically potent natural products, including antibiotic and anticancer compounds. MarPipe aims at further development of antimicrobial and anticancer lead compounds originating from a previous EU project (PharmaSea), and will also explore the bioactivity of deep-sea samples (5000m) collected during the recent Eurofleet-2 project in the sub-Antarctic. The PhD students will thus be involved in all phases of the drug discovery pipeline, from isolation of new microbial strains to pre-clinical development of lead compounds. Importantly, they will also be trained to overcome existing bottlenecks in the field, e.g. low yields and low chemodiversity, isolation of known compounds, toxicity of compounds. The discovery rates of new bioactive antimicrobial and anticancer molecules will be enhanced through 11 PhD projects that cover all phases of the biodiscovery pipeline. As a final outcome of the project, we envisage the creation of a marine biodiscovery start-up company, which will include most of the MarPipe partners. The scientists of the future will be trained to become conscious about the socio-economic and policy context of their work, since several specific MarPipe PhD projects focus on legal, policy, innovation and entrepreneurship themes.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз